FDA Approves Emergency Use of Novavax COVID-19 Vaccine – Consumer Health News
THURSDAY, July 14, 2022 (HealthDay News) — Unvaccinated Americans should soon have a fourth COVID-19 vaccine option.
On Wednesday, the Novavax offer was the last to be obtained Emergency Use Authorization by the US Food and Drug Administration. Advisors from the US Centers for Disease Control and Prevention will meet next week to decide who should be eligible for the vaccine.
“The approval of an additional COVID-19 vaccine expands the vaccine options available to prevent COVID-19, including the most serious outcomes that can occur, such as hospitalization and death,” FDA Commissioner Robert Califf, MD, said in a statement. “Today’s approval provides adults in the United States who have not yet received a COVID-19 vaccine with another option that meets FDA’s strict standards.”
At the moment, the Novavax vaccine is only approved as a first-line vaccine, so those who received any of the other three COVID-19 vaccines cannot use it as a booster shot. The New York Times reported. The company plans to apply for booster approval shortly.
“Today’s FDA emergency use approval of our COVID-19 vaccine gives the United States access to the first protein-based COVID-19 vaccine,” Novavax President and CEO Stanley Erck told a company expression. “This approval reflects the strength of the efficacy and safety data of our COVID-19 vaccine and underscores the urgent need to offer the U.S. population another vaccine option as the pandemic continues.”
Novavax’s vaccine is given in two shots three weeks apart. The Biden administration plans to buy 3.2 million doses, enough for 1.6 million people.